-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is converted Medicine original, reproduced please indicate the source Author: Yun neuroblastoma known as "King of childhood cancer," the title, in the past because of poor efficacy of this tumor, neuroblastoma and the origin of the sympathetic nervous system , Mostly in the adrenal gland or retroperitoneum, the location is very deep, and it is not easy to find in the early stage.
However, this kind of tumor is highly malignant, progresses quickly, and is prone to metastasis to bone marrow, bone and organs.
Recently, Australian researchers discovered a new treatment for neuroblastoma.
The study was published in the journal Nature Communications, entitled "An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability".
The findings are useful for other childhood diseases (such as brain tumors) and adult cancers (such as ovarian cancer).
And prostate cancer) treatment is of great significance.
Source: "Nature Communications" Scientists at the Australian Children's Cancer Institute discovered that a cellular protein called ALYREF plays a vital role in accelerating the role of the cancer driver gene MYCN in neuroblastoma.
The ALYREF gene is located on chromosome 17q25.
3, which codes for a widely expressed nuclear chaperone protein that controls many biological processes.
ALYREF is dysregulated in several human cancers.
Inhibiting the expression of ALYREF can lead to a decline in the proliferation and migration ability of oral squamous cell carcinoma cells.
Despite a lot of research, it is not clear how the expression of ALYREF increases, and how the increase of ALYREF level promotes tumorigenesis.
MYCN is a short-lived transcription factor, strictly controlled by the ubiquitin-proteasome system.
25% of neuroblastoma patients will have MYCN oncogene amplification from 2p24, which is a recognized marker of tumor aggressiveness.
17q21-ter amplification is the most common genetic variant in neuroblastoma, with an incidence rate of 38-65%.
However, the mechanism relationship between MYCN and 17q21-ter is still unclear.
Since there are currently no specific inhibitors for high-risk neuroblastoma patients with these characteristics, there is an urgent need to identify the weaknesses of new targeting molecules.
For some time, scientists have discovered that one-third of children with neuroblastoma have high levels of MYCN in cancer cells, and their prognosis is much worse.
However, MYCN has proven to be an unattainable goal for drug design.
Therefore, scientists turned their attention to finding other molecules that work closely with MYCN.
In this new study, scientists at the Children’s Cancer Institute showed that MYCN relies on ALYREF to drive the growth of neuroblastoma cells.
According to Dr.
Zsuzsi Nagy and lead researchers Professor Glenn Marshall AM and Dr.
Belamy Cheung: "This is the latest discovery in the world.
" "We have demonstrated for the first time that ALYREF binds to and actually controls the MYCN function in neuroblastoma cells.
" Professor Marshall explained, “This means that we now have a new molecule that can be targeted, a new way to enter MYCN and prevent it from promoting the development of cancer.
” Professor Marshall and his team discovered that ALYREF directly binds to MYCN to open another A protein USP3, which prevents MYCN degradation.
This maintains the extremely high levels of MYCN required to drive cancer and therefore can act as an accelerator.
These findings strongly indicate that inhibition of ALYREF may interrupt the cycle, and proved to be a very valuable new treatment strategy for the treatment of high-risk neuroblastoma.
The next step will be to develop an effective and specific ALYREF inhibitor-a drug that can inhibit the action of this molecule, and test it in a laboratory model.
Dr.
Zhang said: “This research lays the foundation for the discovery of new drugs for the treatment of neuroblastoma.
Once a suitable candidate drug is found, we can use it in clinical treatment trials for children with high levels of MYCN and ALYREF.
"It is exciting that targeted therapy for ALYREF may also have therapeutic effects on other types of cancer, such as blood cancer, medulloblastoma, glioblastoma, retinoblastoma, ovarian cancer, and Wilm Tumor and prostate cancer.
Of course, this requires further research to explore.
Reference materials: [1] [2] https://medicalxpress.
com/news/2021-03-world-first-discovery-paves- cancer-treatment.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment options.
If you need health guidance, please go to a regular hospital for treatment.
However, this kind of tumor is highly malignant, progresses quickly, and is prone to metastasis to bone marrow, bone and organs.
Recently, Australian researchers discovered a new treatment for neuroblastoma.
The study was published in the journal Nature Communications, entitled "An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability".
The findings are useful for other childhood diseases (such as brain tumors) and adult cancers (such as ovarian cancer).
And prostate cancer) treatment is of great significance.
Source: "Nature Communications" Scientists at the Australian Children's Cancer Institute discovered that a cellular protein called ALYREF plays a vital role in accelerating the role of the cancer driver gene MYCN in neuroblastoma.
The ALYREF gene is located on chromosome 17q25.
3, which codes for a widely expressed nuclear chaperone protein that controls many biological processes.
ALYREF is dysregulated in several human cancers.
Inhibiting the expression of ALYREF can lead to a decline in the proliferation and migration ability of oral squamous cell carcinoma cells.
Despite a lot of research, it is not clear how the expression of ALYREF increases, and how the increase of ALYREF level promotes tumorigenesis.
MYCN is a short-lived transcription factor, strictly controlled by the ubiquitin-proteasome system.
25% of neuroblastoma patients will have MYCN oncogene amplification from 2p24, which is a recognized marker of tumor aggressiveness.
17q21-ter amplification is the most common genetic variant in neuroblastoma, with an incidence rate of 38-65%.
However, the mechanism relationship between MYCN and 17q21-ter is still unclear.
Since there are currently no specific inhibitors for high-risk neuroblastoma patients with these characteristics, there is an urgent need to identify the weaknesses of new targeting molecules.
For some time, scientists have discovered that one-third of children with neuroblastoma have high levels of MYCN in cancer cells, and their prognosis is much worse.
However, MYCN has proven to be an unattainable goal for drug design.
Therefore, scientists turned their attention to finding other molecules that work closely with MYCN.
In this new study, scientists at the Children’s Cancer Institute showed that MYCN relies on ALYREF to drive the growth of neuroblastoma cells.
According to Dr.
Zsuzsi Nagy and lead researchers Professor Glenn Marshall AM and Dr.
Belamy Cheung: "This is the latest discovery in the world.
" "We have demonstrated for the first time that ALYREF binds to and actually controls the MYCN function in neuroblastoma cells.
" Professor Marshall explained, “This means that we now have a new molecule that can be targeted, a new way to enter MYCN and prevent it from promoting the development of cancer.
” Professor Marshall and his team discovered that ALYREF directly binds to MYCN to open another A protein USP3, which prevents MYCN degradation.
This maintains the extremely high levels of MYCN required to drive cancer and therefore can act as an accelerator.
These findings strongly indicate that inhibition of ALYREF may interrupt the cycle, and proved to be a very valuable new treatment strategy for the treatment of high-risk neuroblastoma.
The next step will be to develop an effective and specific ALYREF inhibitor-a drug that can inhibit the action of this molecule, and test it in a laboratory model.
Dr.
Zhang said: “This research lays the foundation for the discovery of new drugs for the treatment of neuroblastoma.
Once a suitable candidate drug is found, we can use it in clinical treatment trials for children with high levels of MYCN and ALYREF.
"It is exciting that targeted therapy for ALYREF may also have therapeutic effects on other types of cancer, such as blood cancer, medulloblastoma, glioblastoma, retinoblastoma, ovarian cancer, and Wilm Tumor and prostate cancer.
Of course, this requires further research to explore.
Reference materials: [1] [2] https://medicalxpress.
com/news/2021-03-world-first-discovery-paves- cancer-treatment.
html Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment options.
If you need health guidance, please go to a regular hospital for treatment.
